Multiple myeloma (MM) cells suffer from baseline proteotoxicity as the result of an imbalance
between the load of misfolded proteins awaiting proteolysis and the capacity of the ubiquitin …

Proteasome inhibitors, such as bortezomib, are first-line therapy against multiple myeloma
(MM). Unfortunately, patients frequently become refractory to this treatment. The transcription …

Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African
descent with sickle cell trait. We have developed faithful patient-derived RMC models and …

Proteasome inhibitors (PI s) are highly active in multiple myeloma (MM) but resistance is
commonly observed. All clinical stage PI s effectively inhibit chymotrypsin‐like (CT‐L) …

The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the
pathophysiology of hematologic neoplasias, including multiple myeloma. The current review …

Significance: Atherosclerosis is a vascular disease of worldwide significance with fatal
complications such as myocardial infarction, stroke, and peripheral artery disease …

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and
Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but …

Bortezomib is an anti-tumor agent, which inhibits 26S proteasome degrading ubiquitinated
proteins. While apoptotic transcription-associated activation in response to bortezomib has …

Multiple myeloma, the second most common hematological cancer, is currently incurable
due to refractory disease relapse and development of multiple drug resistance. We and …

An increasing number of monoclonal antibodies and derivatives such as antibody-drug
conjugates (ADC) are of the IgG1 and IgG4 isotype with distinct structural and functional …